These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7215416)

  • 41. Haemodynamic effects of intravenous disopyramide in heart failure.
    Jensen G; Sigurd B; Uhrenholt A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):167-73. PubMed ID: 1233215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disopyramide dialysability.
    Lancet; 1978 Jul; 2(8082):214. PubMed ID: 78419
    [No Abstract]   [Full Text] [Related]  

  • 43. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
    Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
    Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 May; 15(5):331-68. PubMed ID: 350555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1976; 199(1-2):41-51. PubMed ID: 1251772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Congestive heart failure caused by oral disopyramide.
    Podrid PJ; Schoeneberger A; Lown B
    N Engl J Med; 1980 Mar; 302(11):614-7. PubMed ID: 7351909
    [No Abstract]   [Full Text] [Related]  

  • 52. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical and hemodynamic effects of disopyramide phosphate administered i.v. in cardiopathic subjects (author's transl)].
    Chiariello M; Santinelli V; Ferro G; Tari MG; Stanislao M; Condorelli M
    G Ital Cardiol; 1979; 9(9):975-83. PubMed ID: 520746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
    Kölle EU; Vollmer KO
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):135S-141S. PubMed ID: 3620273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disopyramide in renal impairment.
    Whiting B; Elliott HL
    Lancet; 1977 Dec 24-31; 2(8052-8053):1363. PubMed ID: 74774
    [No Abstract]   [Full Text] [Related]  

  • 58. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.